β2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway
- PMID: 30306507
- DOI: 10.1007/s11033-018-4332-3
β2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway
Abstract
Psychological stress has been recognized as a well-documented risk factor associated with β2-adrenergic receptor (β2-AR) in the development of pancreatic cancer. Aldo-keto reductase 1 member B1 (AKR1B1) is a potential interacting partner of β2-AR, but the effect of their interaction on pancreatic cancer cells is not known at present. We found a positive correlation between AKR1B1 and β2-AR expression in pancreatic cancer tissue samples, and co-localization of these proteins in the human pancreatic cancer BXPC-3 cell line. Compared to the controls, the CFPAC-1 and PANC-1 pancreatic cancer cells overexpressing β2-AR and AKR1B1 respectively showed significantly higher proliferation rates, which is attributed to higher proportion of cells in the S phase and decreased percentage of early apoptotic cells. Furthermore, overexpression of β2-AR led to a significant increase in the expression of AKR1B1 and phosphorylated extracellular signal-regulated kinase (p-ERK1/2). Overexpression of AKR1B1 significantly decreased β2-AR levels and increased that of p-ERK1/2. Taken together, β2-AR directly interacted with and up-regulated AKR1B1 in pancreatic cancer cells, and promoted their proliferation and inhibited apoptosis via the ERK1/2 pathway. Our findings also highlight the β2-AR-AKR1B1 axis as a potential therapeutic target for pancreatic cancer.
Keywords: AKR1B1; ERK1/2; Pancreatic cancer; Proliferation; β2-AR.
Similar articles
-
β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.Cancer Lett. 2016 Apr 1;373(1):67-76. doi: 10.1016/j.canlet.2016.01.026. Epub 2016 Jan 21. Cancer Lett. 2016. PMID: 26803058
-
Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.Drug Des Devel Ther. 2015 Jan 17;9:575-601. doi: 10.2147/DDDT.S75221. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25632225 Free PMC article.
-
β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation.Circ Res. 2013 Feb 1;112(3):476-86. doi: 10.1161/CIRCRESAHA.112.280735. Epub 2012 Dec 14. Circ Res. 2013. PMID: 23243208 Free PMC article.
-
Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.J Cell Mol Med. 2020 Aug;24(16):8890-8902. doi: 10.1111/jcmm.15581. Epub 2020 Jul 6. J Cell Mol Med. 2020. PMID: 32633024 Free PMC article. Review.
-
Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.Recent Pat Anticancer Drug Discov. 2009 Nov;4(3):246-53. doi: 10.2174/157489209789206931. Recent Pat Anticancer Drug Discov. 2009. PMID: 19522700 Review.
Cited by
-
Mechanism of chronic stress to promote tumor development and the intervention.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Sep 28;47(9):1281-1288. doi: 10.11817/j.issn.1672-7347.2022.210589. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 36411713 Free PMC article. Chinese, English.
-
An Advanced Systems Pharmacology Strategy Reveals AKR1B1, MMP2, PTGER3 as Key Genes in the Competing Endogenous RNA Network of Compound Kushen Injection Treating Gastric Carcinoma by Integrated Bioinformatics and Experimental Verification.Front Cell Dev Biol. 2021 Sep 27;9:742421. doi: 10.3389/fcell.2021.742421. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34646828 Free PMC article.
-
The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer.Mol Biol Rep. 2020 Aug;47(8):6091-6103. doi: 10.1007/s11033-020-05685-z. Epub 2020 Aug 5. Mol Biol Rep. 2020. PMID: 32761301
-
Metabolic enzyme-associated protein-protein interactions (mPPIs) in cancer: potential vulnerability for cancer treatment?Acta Pharmacol Sin. 2025 Jun 20. doi: 10.1038/s41401-025-01601-y. Online ahead of print. Acta Pharmacol Sin. 2025. PMID: 40542281 Review.
-
Integration of metabolites from meta-analysis with transcriptome reveals enhanced SPHK1 in PDAC with a background of pancreatitis.BMC Cancer. 2022 Jul 19;22(1):792. doi: 10.1186/s12885-022-09816-6. BMC Cancer. 2022. PMID: 35854233 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous